HRP20181973T1 - Poboljšana anti humana fraktalkinska protutijela i njihova uporaba - Google Patents

Poboljšana anti humana fraktalkinska protutijela i njihova uporaba

Info

Publication number
HRP20181973T1
HRP20181973T1 HRP20181973TT HRP20181973T HRP20181973T1 HR P20181973 T1 HRP20181973 T1 HR P20181973T1 HR P20181973T T HRP20181973T T HR P20181973TT HR P20181973 T HRP20181973 T HR P20181973T HR P20181973 T1 HRP20181973 T1 HR P20181973T1
Authority
HR
Croatia
Prior art keywords
fraktalkine
antibodies
improved anti
anti human
human
Prior art date
Application number
HRP20181973TT
Other languages
English (en)
Inventor
Miyuki Nishimura
Yoshimasa Sakamoto
Tetsu Kawano
Toshio Imai
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43922220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20181973(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of HRP20181973T1 publication Critical patent/HRP20181973T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HRP20181973TT 2009-10-30 2018-11-23 Poboljšana anti humana fraktalkinska protutijela i njihova uporaba HRP20181973T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
EP10826929.1A EP2493930B1 (en) 2009-10-30 2010-10-28 Improved anti human Fraktalkine antibodies and uses thereof
PCT/JP2010/069653 WO2011052799A1 (en) 2009-10-30 2010-10-28 Compositions and methods for treating inflammatory disorders

Publications (1)

Publication Number Publication Date
HRP20181973T1 true HRP20181973T1 (hr) 2019-01-25

Family

ID=43922220

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181973TT HRP20181973T1 (hr) 2009-10-30 2018-11-23 Poboljšana anti humana fraktalkinska protutijela i njihova uporaba

Country Status (31)

Country Link
US (1) US8932592B2 (hr)
EP (1) EP2493930B1 (hr)
JP (2) JP5631991B2 (hr)
KR (2) KR101627605B1 (hr)
CN (1) CN102597003B (hr)
AR (2) AR078796A1 (hr)
AU (1) AU2010312408B2 (hr)
BR (1) BR112012010266A2 (hr)
CA (1) CA2778895C (hr)
CL (2) CL2012001143A1 (hr)
CY (1) CY1121167T1 (hr)
DK (1) DK2493930T3 (hr)
ES (1) ES2698389T3 (hr)
HR (1) HRP20181973T1 (hr)
HU (1) HUE041952T2 (hr)
IL (1) IL219470A (hr)
JO (1) JO3437B1 (hr)
LT (1) LT2493930T (hr)
MX (1) MX2012005052A (hr)
MY (1) MY158481A (hr)
NZ (1) NZ599779A (hr)
PE (1) PE20121645A1 (hr)
PL (1) PL2493930T3 (hr)
PT (1) PT2493930T (hr)
RS (1) RS58142B1 (hr)
RU (1) RU2569109C2 (hr)
SI (1) SI2493930T1 (hr)
TW (1) TWI414308B (hr)
UA (1) UA105073C2 (hr)
WO (1) WO2011052799A1 (hr)
ZA (1) ZA201203002B (hr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
CA2968382A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
WO2020214166A1 (en) * 2019-04-17 2020-10-22 The Governors Of The University Of Alberta Treatment of autoimmune liver disease
WO2020218232A1 (ja) 2019-04-23 2020-10-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチ治療のためのバイオマーカー
CN113087795A (zh) * 2019-12-23 2021-07-09 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
TW202227483A (zh) 2020-10-30 2022-07-16 日商衛材R&D企管股份有限公司 醫藥組合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
WO1997002290A1 (fr) * 1995-06-30 1997-01-23 Mochida Pharmaceutical Co., Ltd. ANTICORPS DE LIGAND ANTIFas ET PROCEDE D'EPREUVE LE FAISANT INTERVENIR
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
CA2240409C (en) 1996-01-24 2011-03-22 Schering Corporation Mammalian cx3c chemokine genes
US6043086A (en) 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
AU730989B2 (en) 1996-05-07 2001-03-22 Millennium Pharmaceuticals, Inc. Neurotactin and uses therefor
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
US6420121B1 (en) 1998-08-31 2002-07-16 Oregon Health Sciences University Prevention of cell migration initiation with CMV US28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
AU2000273378A1 (en) 2000-02-18 2001-08-27 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ｃｘ３ｃｒ１抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
ES2330731T3 (es) 2001-08-30 2009-12-15 Chemocentryx, Inc. Compuestos biciclicos como inhibidores de la union de quimioquina a us28.
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
WO2005032589A1 (ja) 2003-10-02 2005-04-14 Japan Science And Technology Agency Ｇｖｈｄの予防及び治療
KR20060120014A (ko) 2003-10-07 2006-11-24 아스트라제네카 아베 케모킨, 특히 ｃｘ3ｃｒ1 수용체 길항제로서 유용한 신규한2-치환된 4-아미노-티아졸로[4,5-ｄ]피리미딘
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
JP4979388B2 (ja) 2004-10-29 2012-07-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 炎症性疾患治療剤
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
SI2094728T1 (sl) 2006-10-26 2013-06-28 Janssen Biotech, Inc. Postopki za uporabo za humano-adaptivnost monoklonskih protiteles
EP2197911A2 (en) * 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations

Also Published As

Publication number Publication date
CL2015000114A1 (es) 2015-04-10
PE20121645A1 (es) 2012-12-06
MY158481A (en) 2016-10-14
EP2493930B1 (en) 2018-09-19
CN102597003B (zh) 2016-03-23
ES2698389T3 (es) 2019-02-04
ZA201203002B (en) 2013-06-26
NZ599779A (en) 2014-03-28
JP2013509158A (ja) 2013-03-14
CY1121167T1 (el) 2020-05-29
CA2778895A1 (en) 2011-05-05
JO3437B1 (ar) 2019-10-20
JP2015027304A (ja) 2015-02-12
KR20120104560A (ko) 2012-09-21
HUE041952T2 (hu) 2019-06-28
RU2012122203A (ru) 2013-12-10
UA105073C2 (uk) 2014-04-10
RS58142B1 (sr) 2019-02-28
AU2010312408B2 (en) 2015-07-09
LT2493930T (lt) 2019-01-10
TW201127401A (en) 2011-08-16
TWI414308B (zh) 2013-11-11
CA2778895C (en) 2018-08-07
SI2493930T1 (sl) 2018-12-31
JP5631991B2 (ja) 2014-11-26
KR102099596B1 (ko) 2020-04-10
DK2493930T3 (en) 2018-12-17
AR078796A1 (es) 2011-12-07
RU2569109C2 (ru) 2015-11-20
IL219470A0 (en) 2012-06-28
KR20160066055A (ko) 2016-06-09
WO2011052799A1 (en) 2011-05-05
IL219470A (en) 2017-10-31
AU2010312408A1 (en) 2012-06-21
US8932592B2 (en) 2015-01-13
AR109533A2 (es) 2018-12-19
CL2012001143A1 (es) 2012-10-05
KR101627605B1 (ko) 2016-06-07
PT2493930T (pt) 2018-11-29
CN102597003A (zh) 2012-07-18
EP2493930A4 (en) 2013-12-04
BR112012010266A2 (pt) 2016-12-06
PL2493930T3 (pl) 2019-03-29
US20120213799A1 (en) 2012-08-23
MX2012005052A (es) 2012-05-29
EP2493930A1 (en) 2012-09-05

Similar Documents

Publication Publication Date Title
HRP20181973T1 (hr) Poboljšana anti humana fraktalkinska protutijela i njihova uporaba
ZA201107486B (en) Anti-tnf-x antibodies and their uses
EP2494062A4 (en) ANTI-GLP-1R ANTIBODIES AND THEIR USES
GB0922434D0 (en) antibodies and fragments thereof
HK1167666A1 (en) Anti-fgfr3 antibodies and methods using same -fgfr3
ZA201108310B (en) Blocking anti-dkk-1 antibodies and their uses
LT2946791T (lt) Anti-cd277 antikūnai ir jų panaudojimas
HK1179981A1 (zh) 的抗體及其用途
HK1195776A1 (zh) -α 抗-α 抗體及其應用
HK1186195A1 (zh) 抗人 的抗體及其用途
IL220536A0 (en) Anti - bv8 antibodies and uses thereof
GB0807018D0 (en) Antibodies and treatment
EP2632952A4 (en) ANTI-SOD1 ANTIBODIES AND USES THEREOF
IL214355A0 (en) Antibodies against human tweak and uses thereof
EP2507263A4 (en) ANTI-IGF-IR ANTIBODIES AND ITS USES
IL219136A0 (en) Anti-hepsin antibodies and methods using same
GB0903151D0 (en) Antibody uses and methods
IL214527A0 (en) Anti-mst1r antibodies and uses thereof
EP2545378A4 (en) ANTI-LG3 ANTIBODIES AND USES THEREOF
GB0906115D0 (en) Antibody and uses thereof
GB0911407D0 (en) Antibody and diagnostic use